Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) announced that all 14 directors attended the nineteenth meeting of the fourth board session on 27 April 2026. The meeting complied with PRC Company Law and the firm’s Articles of Association, rendering its resolutions legal and valid.

Key approvals:

1. 2026 First-Quarter Report • The Audit Committee reviewed and endorsed the report before submitting it to the full board, which passed it unanimously (14 votes in favor, none against or abstained). Full details have been filed with the Shanghai Stock Exchange.

2. 2026 A-Share Employee Stock Ownership Plan (ESOP) • The draft ESOP and its summary aim to enhance employee–shareholder alignment, strengthen workforce cohesion, and support long-term corporate development. • Supporting Administrative Measures for the ESOP were simultaneously approved. • Both items require shareholder approval at the forthcoming general meeting. • Voting outcome for each ESOP-related resolution: 14 votes in favor, none against or abstained.

3. Authorisation to Implement and Manage the ESOP • The board will seek shareholder authorisation to manage the ESOP’s full life cycle, including plan amendments, participant eligibility, lock-up and unlocking arrangements, repurchase or cancellation of shares, selection of asset management institutions, and other necessary operational matters. • The authorisation remains effective from the date of shareholder approval until plan termination.

The resolutions underscore Junshi Bio’s emphasis on governance transparency and talent incentives as it advances its strategic objectives.